Wan Qi, Deng Zhishan, Wu Fan, Zheng Youlan, Yang Huajing, Zhao Ningning, Dai Cuiqiong, Xiao Shan, Wen Xiang, Peng Jieqi, Lu Lifei, Zhou Kunning, Wu Xiaohui, Tang Gaoying, Yang Changli, Chen Shengtang, Huang Jianhui, Huang Yongqing, Yu Shuqing, Hong Wei, Zhou Yumin, Ran Pixin
State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease and National Center for Respiratory Medicine and Guangzhou Institute of Respiratory Health and The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Guangzhou National Laboratory, Guangzhou, China.
Ann Am Thorac Soc. 2025 May;22(5):669-678. doi: 10.1513/AnnalsATS.202404-408OC.
Previous studies have identified exercise intolerance in patients with mild-to-moderate chronic obstructive pulmonary disease (COPD). The association of exercise tolerance with lung function decline and acute exacerbation risk in mild-to-moderate COPD is unclear, especially in the community population. We evaluated exercise tolerance in patients with mild-to-moderate COPD and analyzed its associations with respiratory health outcomes. We analyzed data from the community-based ECOPD (Early Chronic Obstructive Pulmonary Disease) study of patients with mild-to-moderate COPD (postbronchodilator forced expiratory volume in 1 second (FEV):forced vital capacity < 0.70 and FEV ≥ 50% predicted). Patients who completed questionnaires, spirometry, and cardiopulmonary exercise testing at baseline were included. Annual exacerbation assessment and spirometry were conducted for 2 years consecutively. Exercise tolerance was defined as the percentage of predicted peak oxygen uptake ([Formula: see text]o% predicted). We analyzed the association between exercise tolerance, annual lung function decline, and acute exacerbation risk. Overall, 338 patients were included in the baseline analysis, and 319 completed the 2-year follow up. The mean ± standard deviation of [Formula: see text]o% predicted was 79.8 ± 13.7%. Low [Formula: see text]o% predicted was associated with more chronic respiratory symptoms, worse lung function, severer emphysema, and air trapping at baseline. During the 2-year follow up, a decrease of 13.7% (1 standard deviation) in [Formula: see text]o% predicted was associated with a decline in prebronchodilator FEV:forced vital capacity (difference, 0.4% [95% confidence interval, 0.1-0.7%]; = 0.003) and higher total exacerbation risk (relative risk, 1.25 [95% confidence interval, 1.08-1.46]; = 0.004) after adjustment. Patients with mild-to-moderate COPD and exercise intolerance have worse respiratory health outcomes, for which low exercise tolerance is a prognostic marker. Clinical trial registered with www.chictr.org.cn (ChiCTR1900024643).
既往研究已证实轻度至中度慢性阻塞性肺疾病(COPD)患者存在运动不耐受。运动耐量与轻度至中度COPD患者肺功能下降及急性加重风险之间的关联尚不清楚,尤其是在社区人群中。我们评估了轻度至中度COPD患者的运动耐量,并分析了其与呼吸健康结局的关联。我们分析了基于社区的轻度至中度COPD患者(支气管扩张剂后1秒用力呼气容积(FEV):用力肺活量<0.70且FEV≥预测值的50%)的ECOPD(早期慢性阻塞性肺疾病)研究数据。纳入了在基线时完成问卷、肺功能测定和心肺运动试验的患者。连续2年进行年度加重评估和肺功能测定。运动耐量定义为预测的峰值摄氧量百分比([公式:见正文]o%预测值)。我们分析了运动耐量、年度肺功能下降和急性加重风险之间的关联。总体而言,338例患者纳入基线分析,319例完成了2年随访。预测的[公式:见正文]o%的平均值±标准差为79.8±13.7%。预测的[公式:见正文]o%低与更多慢性呼吸道症状、更差的肺功能、更严重的肺气肿以及基线时的气体潴留相关。在2年随访期间,预测的[公式:见正文]o%下降13.7%(1个标准差)与支气管扩张剂前FEV:用力肺活量下降相关(差异为0.4%[95%置信区间,0.1 - 0.7%];P = 0.003),且在调整后总加重风险更高(相对风险,1.25[95%置信区间,1.08 - 1.46];P = 0.004)。轻度至中度COPD且有运动不耐受的患者呼吸健康结局更差,其中运动耐量低是一个预后指标。在www.chictr.org.cn注册的临床试验(ChiCTR1900024643)。